{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:53:41Z","timestamp":1786550021655,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/ajg.2015.439","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T08:01:42Z","timestamp":1454400102000},"page":"381-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial"],"prefix":"10.14309","volume":"111","author":[{"given":"Jyh-Ming","family":"Liou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Jyh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hao","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yuh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiing-Chyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeng-Yih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsiung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Yueh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Tung","family":"Shun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Feng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Wei","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaw-Town","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20210210","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials.","volume":"348","author":"Ford","year":"2014","journal-title":"BMJ"},{"key":"R2-24-20210210","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1136\/gutjnl-2012-302240","article-title":"The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention.","volume":"62","author":"Lee","year":"2013","journal-title":"Gut"},{"key":"R3-24-20210210","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1111\/j.1572-0241.2007.01393.x","article-title":"Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection.","volume":"102","author":"Chey","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R4-24-20210210","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy.","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ"},{"key":"R5-24-20210210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R6-24-20210210","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infectionThe Maastricht IV Florence Consensus Report.","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"R7-24-20210210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption.","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"R8-24-20210210","doi-asserted-by":"crossref","first-page":"e0124199","DOI":"10.1371\/journal.pone.0124199","article-title":"The primary resistance of Helicobacter pylori in Taiwan after the national policy to restrict antibiotic consumption and its relation to virulence factors-A nationwide study.","volume":"10","author":"Liou","year":"2015","journal-title":"PLoS One"},{"key":"R9-24-20210210","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MCG.0b013e318254ebdd","article-title":"Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.","volume":"47","author":"Gisbert","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"R10-24-20210210","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/gut.2009.198309","article-title":"Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design.","volume":"59","author":"Liou","year":"2010","journal-title":"Gut"},{"key":"R11-24-20210210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(12)61579-7","article-title":"Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.","volume":"381","author":"Liou","year":"2013","journal-title":"Lancet"},{"key":"R12-24-20210210","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(11)60825-8","article-title":"14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.","volume":"378","author":"Greenberg","year":"2011","journal-title":"Lancet"},{"key":"R13-24-20210210","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/0003-4819-146-8-200704170-00006","article-title":"Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial.","volume":"146","author":"Vaira","year":"2007","journal-title":"Ann Intern Med"},{"key":"R14-24-20210210","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2036.2010.04274.x","article-title":"Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.","volume":"31","author":"Molina-Infante","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R15-24-20210210","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5754\/hge11075","article-title":"Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication.","volume":"58","author":"Ozdil","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"R16-24-20210210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1523-5378.2012.00993.x","article-title":"Levofloxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China.","volume":"17","author":"Qian","year":"2012","journal-title":"Helicobacter"},{"key":"R17-24-20210210","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/jac\/dkr217","article-title":"Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.","volume":"66","author":"Liou","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R18-24-20210210","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/ajg.2014.24","article-title":"The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.","volume":"109","author":"Camargo","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R19-24-20210210","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/17474124.2014.859522","article-title":"Evidence-based recommendations for successful Helicobacter pylori treatment.","volume":"8","author":"Wu","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R20-24-20210210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/jac\/dks407","article-title":"Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial.","volume":"68","author":"Liou","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R21-24-20210210","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1128\/AAC.01131-10","article-title":"Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.","volume":"55","author":"Liou","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-24-20210210","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1523-5378.2007.00518.x","article-title":"A report card to grade Helicobacter pylori therapy.","volume":"12","author":"Graham","year":"2007","journal-title":"Helicobacter"},{"key":"R23-24-20210210","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gut.2010.215350","article-title":"Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial.","volume":"59","author":"Romano","year":"2010","journal-title":"Gut"},{"key":"R24-24-20210210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.gastro.2012.03.043","article-title":"Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.","volume":"143","author":"Federico","year":"2012","journal-title":"Gastroenterology"},{"key":"R25-24-20210210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.cgh.2010.07.002","article-title":"Helicobacter pylori eradication therapy research: Ethical issues and description of results.","volume":"8","author":"Graham","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-24-20210210","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2015439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015439","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2015439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201603000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:11:23Z","timestamp":1786547483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201603000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2015.439","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}